KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial.TrialsPMID 38167339PMC107632192024-Jan-020.80The record is a protocol for a non-drug (radiotherapy) trial, not a formal result report of a drug-containing intervention with a time-to-event efficacy endpoint.待处理
Salivary Electrostimulation in the Treatment of Radiation Therapy-Induced Xerostomia (LEONIDAS-2): A Multicenter, Randomized, Double-Masked, Sham-Controlled, Phase 3 Trial.Int J Radiat Oncol Biol PhysPMID 36933846无 PMCID2024-Jan-010.93干预为非药物单独策略,未满足药物干预要求。待处理
Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie Génito-Urinaire de Quebec Led Phase 3 Trial.Int J Radiat Oncol Biol PhysPMID 37224928无 PMCID2024-Jan-010.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。待处理
Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial.J Clin OncolPMID 37748124PMC107300672024-Jan-010.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.JAMA CardiolPMID 37966817PMC106522192024-Jan-010.98未发现恶性肿瘤人群证据。待处理
Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial.VaccinePMID 38042698PMC107338622024-Jan-010.98未发现恶性肿瘤人群证据。待处理
DELIVER: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy.J Acquir Immune Defic SyndrPMID 38055292PMC114434172024-Jan-010.98未发现恶性肿瘤人群证据。待处理
Sublingual immunotherapy tablets in monosensitized and polysensitized adults with allergic rhinoconjunctivitis.Allergy Asthma ProcPMID 38151733无 PMCID2024-Jan-010.98未发现恶性肿瘤人群证据。待处理
Acceptability, feasibility and preliminary efficacy of low-moderate intensity Constraint Induced Aphasia Therapy and Multi-Modality Aphasia Therapy in chronic aphasia after stroke.Top Stroke RehabilPMID 37036031无 PMCID2024-Jan0.98未发现恶性肿瘤人群证据。待处理
Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study.Clin Gastroenterol HepatolPMID 37061109无 PMCID2024-Jan0.98未发现恶性肿瘤人群证据。待处理
Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up.Int Forum Allergy RhinolPMID 37345861无 PMCID2024-Jan0.98未发现恶性肿瘤人群证据。待处理
ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis.J Cyst FibrosPMID 37455237无 PMCID2024-Jan0.98未发现恶性肿瘤人群证据。待处理
Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial.Lancet Infect DisPMID 37625434无 PMCID2024-Jan0.98未发现恶性肿瘤人群证据。待处理
Low-Dose Remifentanil in Preterm Cesarean Section with General Anesthesia: A Randomized Controlled Trial.Paediatr DrugsPMID 37713021无 PMCID2024-Jan0.98未发现恶性肿瘤人群证据。待处理
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group.Eur J Nucl Med Mol ImagingPMID 37735258PMC107741572024-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.BioDrugsPMID 37737952无 PMCID2024-Jan0.95The record describes a Phase III randomized trial of a drug (ixekizumab) for active radiographic axial spondyloarthritis, which is an autoimmune/inflammatory condition, not an oncology (human malignant neoplasm) indication. The primary efficacy endpoint is a proportion (ASAS40 response), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP, and no Kaplan-Meier or HR analysis for such an endpoint is reported. Therefore, it does not meet the core eligibility criteria for the oncology KM digitization cohort.待处理
Model-Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.Clin Pharmacol TherPMID 37777832无 PMCID2024-Jan0.80The record is from a randomized phase II trial with a drug intervention (xevinapant) and presents original results. However, it does not meet the required criteria: it is a phase II study, not a phase III or phase IIIb trial, and its primary efficacy endpoint is locoregional control (not a standard time-to-event endpoint like OS, PFS, DFS, etc.) with no mention of Kaplan-Meier analysis or hazard ratios. Therefore, it is ineligible.待处理
Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study.Diabetes Obes MetabPMID 37794628无 PMCID2024-Jan0.98未发现恶性肿瘤人群证据。待处理
Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.Ann HematolPMID 37804344PMC107615222024-Jan0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Participant Safety in Multisite, Randomized, Double-Blind, Placebo-Controlled Clinical Trials in Hospice/Palliative Care: Data from the Contracted Studies of the Australian National Palliative Care Clinical Studies Collaborative.J Palliat MedPMID 37824800无 PMCID2024-Jan0.98未发现恶性肿瘤人群证据。待处理
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.Ann OncolPMID 37866811无 PMCID2024-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Effectiveness of Liposomal Bupivacaine With Bupivacaine Hydrochloride vs Bupivacaine Hydrochloride Alone as a Local Anesthetic for Children Undergoing Ambulatory Urologic Surgery: The Baby ORIOLES Randomized Clinical Trial.J UrolPMID 37871332无 PMCID2024-Jan0.98未发现恶性肿瘤人群证据。待处理
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.Ann OncolPMID 37871702无 PMCID2024-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Ultra-rapid lispro improved postprandial glucose control compared to insulin lispro in predominantly Chinese patients with type 1 diabetes: A prospective, randomized, double-blind phase 3 study.Diabetes Obes MetabPMID 37871985无 PMCID2024-Jan0.98未发现恶性肿瘤人群证据。待处理
Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial.Br J CancerPMID 37903909PMC107817432024-Jan1.00命中用户提供的消化道肿瘤阳性参考集。待处理
Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).Ann Surg OncolPMID 37903951PMC106958692024-Jan0.80The record describes a preplanned observational cohort study assessing the impact of imaging-guided localization on surgical performance within a larger phase-III trial. While the parent trial is phase-III, randomized, oncologic, human, and drug-containing, this specific report does not present a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The analysis focuses on surgical/procedural outcomes (lymph node counts, residual disease), which are not time-to-event endpoints. Therefore, it is not eligible for the oncology KM digitization cohort.待处理
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial.Ann OncolPMID 37922989无 PMCID2024-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD).Am J HematolPMID 37929318无 PMCID2024-Jan0.98未发现恶性肿瘤人群证据。待处理
Clinical Bridging From Prefilled Syringe to On-body Injector for Risankizumab in Crohn's Disease.Clin TherPMID 37932155无 PMCID2024-Jan0.98未发现恶性肿瘤人群证据。待处理
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis.Diabetes Obes MetabPMID 37932236无 PMCID2024-Jan0.98未发现恶性肿瘤人群证据。待处理
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.LeukemiaPMID 37935977PMC117293992024-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial.Lancet HaematolPMID 37980924无 PMCID2024-Jan0.85While the trial meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result, the primary efficacy endpoint is a non-inferiority/superiority comparison of venous thromboembolism incidence (reported as relative risk), not a time-to-event oncology endpoint like OS or PFS. Therefore, it does not meet the time-to-event criterion required for inclusion in this cohort.待处理
Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies.AllergyPMID 37988255无 PMCID2024-Jan0.98未发现恶性肿瘤人群证据。待处理
Long-term outcomes of neo-adjuvant chemotherapy on borderline resectable oral cavity cancers: Real-world data of 3266 patients and implications for clinical practice.Oral OncolPMID 37988838无 PMCID2024-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer.Gastric CancerPMID 37989806无 PMCID2024-Jan0.95All required criteria are explicitly met: it is an original, formal-result report of a Phase III randomized trial in human oncology (gastric cancer) evaluating a drug intervention (S-1) with primary/key secondary time-to-event efficacy endpoints (RFS and OS, reported with Kaplan-Meier estimates and HRs).待处理
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.BioDrugsPMID 37991693PMC107898332024-Jan0.98未发现恶性肿瘤人群证据。待处理
Phase III clinical trial comparing the efficacy and safety of adamgammadex with sugammadex for reversal of rocuronium-induced neuromuscular block.Br J AnaesthPMID 38007377无 PMCID2024-Jan0.98未发现恶性肿瘤人群证据。待处理
Improvements in pincer nail deformity occur earlier and last longer when acetylcysteine gel is added to an overcurvature-correcting device: Results of a phase 3, multicenter, randomized, vehicle-controlled, investigator-blinded study.J DermatolPMID 38009825PMC114839672024-Jan0.98未发现恶性肿瘤人群证据。待处理
Thrombolysis with Recombinant Human Prourokinase 4.5-6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial.CNS DrugsPMID 38030867PMC108110052024-Jan0.98未发现恶性肿瘤人群证据。待处理
Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma.Gynecol OncolPMID 38052110无 PMCID2024-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.Lancet Diabetes EndocrinolPMID 38061371PMC76155912024-Jan0.98未发现恶性肿瘤人群证据。待处理
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.Lancet Diabetes EndocrinolPMID 38061372PMC76185362024-Jan0.98未发现恶性肿瘤人群证据。待处理
Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus.Diabetes Res Clin PractPMID 38061446无 PMCID2024-Jan0.98未发现恶性肿瘤人群证据。待处理
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet HaematolPMID 38065203无 PMCID2024-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.Lancet OncolPMID 38101431无 PMCID2024-Jan0.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。待处理
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.Lancet OncolPMID 38101433无 PMCID2024-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study.ESMO OpenPMID 38118368PMC108377732024-Jan0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.Lancet HaematolPMID 38135371无 PMCID2024-Jan0.95While the study is an oncology Phase 3 randomized trial with a drug intervention and reports original results, it does not meet the cohort's inclusion criteria because the primary endpoint is pharmacokinetic equivalence (AUC), not a time-to-event efficacy endpoint such as overall survival, progression-free survival, or disease-free survival. No Kaplan-Meier curves or hazard ratios for such endpoints are described in the provided abstract.待处理
Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia.Int J Rheum DisPMID 38140854无 PMCID2024-Jan0.98未发现恶性肿瘤人群证据。待处理
Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL).Intensive Care MedPMID 38172296PMC108109412024-Jan0.98未发现恶性肿瘤人群证据。待处理